DAFTAR PUSTAKA
1.
Kementerian Kesehatan RI. Tuberkulosis: Temukan, Obati Sampai
Sembuh. Jakarta: Kementerian Kesehatan RI; 2015.
2.
World Health Organization. Global Tuberculosis Report 2015, 20th
Edition. Geneva (Swiss): World Health Organization; 2015.
3.
World Health Organization. Global Update on the Health Sector Response
to HIV, 2014. Geneva (Swiss): World Health Organization; 2014.
4.
Lorent N, Sebatunzi O, Mukeshimana G, Ende J Van den, Clerinx J.
Incidence and Risk Factors of Serious Adverse Events during
Antituberculous Treatment in Rwanda : A Prospective Cohort Study.
PLoS
ONE
. 2011;6(5):1-9.
5.
Padmapriyadarsini C, Narendran G, Swaminathan S. Diagnosis &
Treatment of Tuberculosis in HIV Co-infected Patients.
Indian J Med Res
.
2011;134(6):850-65.
6.
World Health Organization. Consolidated Guidelines on the Use of
Antiretroviral Drugs For Treating and Preventing HIV Infection. Geneva
(Swiss): World Health Organization; 2013.
7.
Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment Optimization
in Patients Co-Infected with HIV and Mycobacterium tuberculosis
Infections: Focus on Drug–Drug Interactions with Rifamycins.
Clin
Pharmacokinet
. 2014;53(6):489-507.
2010;36(June):626-40.
9.
Kementerian
Kesehatan
Republik
Indonesia
Direktorat
Jenderal
Pengendalian Penyakit dan Penyehatan Lingkungan. Pedoman Nasional
Pengendalian Tuberkulosis. Jakarta: Kementerian Kesehatan Republik
Indonesia; 2014.
10.
Istiantoro YH, Setiabudy R. Tuberkulostatik dan Leprostatik. In:
Farmakologi Dan Terapi Edisi 5
. Jakarta: Balai Penerbit FKUI;
2009:613-20.
11.
Lai HM, Mazlan NA, Yusoff SAM, Harun SN, Wee LJ, Thambrin FRM.
Management of Side Effects and Drug Interactions of Anti-mycobacterial
in Tuberculosis Management of Side Effects and Drug Interactions of
Anti-mycobacterial in Tuberculosis.
WebmedCentral Infect Dis
. 2011;2(12):1-9.
12.
Farazi A, Sofian M, Jabbariasl M, Keshavarz S. Adverse Reactions to
Antituberculosis Drugs in Iranian Tuberculosis Patients.
Tuberc Res Treat
.
2014;2014:6 pages.
13.
Louisa M, Setiabudy R. Antivirus. In:
Farmakologi Dan Terapi Edisi 5
.
Jakarta: Balai Penerbit FKUI; 2009:651-4.
14.
Nash J, Orrell C, Pakade Y, Venter F, Wilson D. Adult Antiretroviral
Therapy Guidelines 2014 By the Southern African HIV Clinicians Society.
S Afr J HIV Med
. 2015;15(4):121-43.
16.
Patel KK, Patel AK, Ranjan RR, Patel AR, Patel JK. Tenofovir-associated
Renal Dysfunction in Clinical Practice : An observational cohort from
western India.
Indian J Sex Transm Dis
. 2010;31(1):30-4.
17.
Lawn SD, Meintjes G, Mcilleron H, Harries AD, Wood R. Management of
HIV-associated Tuberculosis in Resource-
limited Settings : a state
-of-the-art review.
BMC Med
. 2013;11:1-16.
18.
Reust CE. Common Adverse Effects of Antiretroviral Therapy for HIV
Disease.
Am Fam Physician
. 2011;83(12):1443-51.
19.
Safrin S. Antiviral Agents. In:
Basic and Clinical Pharmacology
. 9th ed.
United States: McGraw-Hill Companies Inc.; 2004:1130-41.
20.
U.S Food and Drug Administration. Stavudine [Internet]. 2002 [updated
2002
Jan
24;
cited
2016
Apr
26].
Available
from:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020412s029,02
0413s020lbl.pdf
21.
U.S Food and Drug Administration. Nevirapine [Internet]. 2005 [updated
2005
Jan
11;
cited
2016
Apr
26].
Available
from:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20636s025,209
33s014lbl.pdf
22.
Mukonzo JK, Okwera A, Nakasujja N, Luzze H, Sebuwufu D,
Ogwal-okeng J, et al. Influence of Efavirenz Pharmacokinetics and
Pharmacogenetics on Neuropsychological Disorders in Ugandan
HIV-positive Patients with or without Tuberculosis : a prospective cohort study.
23.
Semvua HH, Kibiki GS. Atripla R / anti-TB combination in TB / HIV
patients . Drug in focus.
BMC Res Notes
. 2011;4(1):511.
24.
Su S, Gauggel S. Neuropsychiatric Complications of Efavirenz Therapy :
Suggestions for a New Research Paradigm.
J Neuropsychiatry Clin
Neurosci
. 2010;22(4):361-9.
25.
Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan
Republik Indonesia Nomor 87 Tahun 2014 Tentang Pedoman Pengobatan
Antiretroviral. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014.
26.
Kementerian
Kesehatan
Republik
Indonesia.
Pedoman
Nasional
Tatalaksana Klinis Infeksi HIV Dan Terapi Antiretroviral Pada Orang
Dewasa. Jakarta: Kementerian Kesehatan Republik Indonesia; 2011.
27.
Pozniak AL, Coyne KM, Miller RF, Lipman MCI, Freedman AR, Ormerod
LP, et al. British HIV Association guidelines for the treatment of TB / HIV
coinfection 2011.
HIV Med
. 2011;12(9):517-24.
28.
Centers for Disease Control and Prevention [Internet]. Atlanta: Centers for
Disease Control and Prevention; 2015 [updated 2014 Sept 22; cited 2015
Dec
29].
Available
from:
http://www.cdc.gov/tb/publications/guidelines/tb_hiv_drugs/recommendati
ons02.htm
29.
Khoo SH, Gibbons S, Seden K, Back DJ.
SYSTEMATIC REVIEW : Drug
-Drug Interactions between Antiretrovirals and Medications Used to Treat
TB , Malaria , Hepatitis B & C and Opioid Dependence
. Vol 5656.
Survival Guide for Clinicians, Second Edition
. California: Curry
International Tuberculosis Center; 2011:145-70.
31.
Mehta SA, Ahmed A, Laverty M, Holzman RS, Valentine F. Sex
Differences in the Incidence of Peripheral Neuropathy Among Kenyans
Initiating Antiretroviral Therapy.
Clin Infect Dis
. 2011;53(5):490-6.
32.
Nemaura T, Dhoro M, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa
C. AIDS & Clinical Evaluation of the Prevalence , Progression and
Severity of Common Adverse Reactions (Lipodystrophy , CNS , Peripheral
Neuropathy, and Hypersensitivity Reactions) Associated with
Anti-Retroviral Therapy (ART) and Anti-Tuberculosis Treatmen.
J AIDS Clin
Res
. 2013;4(4).
33.
Jong E, Conradie F, Berhanu R, Black A, John MA, Meintjes G, et al.
Consensus statement : Management of drug
-induced liver injury in
HIV-positive patients treated for TB.
S Afr J HIV Med
. 2013;14(3):113-9.
34.
Bayupurnama P. Hepatotoksisitas Imbas Obat. In:
Buku Ajar Ilmu Penyakit
Dalam Jilid II, Edisi VI
. Jakarta: InternaPublishing; 2014:2009.
35.
Gaida R, Truter I, Grobler C. Efavirenz : A review o
f the epidemiology ,
severity and management of neuropsychiatric side-effects.
S Afr J psyc
.
2015;21(3):94-7.
36.
Waheed S, Attia D, Estrella MM, Zafar Y, Atta MG, Lucas GM, et al.
Proximal Tubular Dysfunction and Kidney Injury Associated with
Tenofovir in HIV Patients : a case series.
Clin Kidney J
. 2015:1-6.
2013;24(10):1519-27.
38.
Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ.
New insights into the mechanism of aminoglycoside nephrotoxicity: an
integrative point of view.
Kidney Int
. 2011;79(1):33-45.
39.
Huth ME, Ricci AJ, Cheng AG. Mechanisms of Aminoglycoside
Ototoxicity and Targets of Hair Cell Protection.
Int J Otolaryngol
.
2011;2011:19 pages.
40.
Mintzer DM, Billet SN, Chmielewski L. Drug-Induced Hematologic
Syndromes.
Adv Hematol
. 2009;2009.
41.
Mustak H, Rogers G, Cook C. Ethambutol Induced Toxic Optic
Neuropathy in HIV.
Int J Ophthalmol
. 2013;6(4):542-5.
42.
Pregled V, Dragovi G, Danilovi D, Dimi A, Jevtovi D. Lipodystrophy
Induced by Combination Antiretroviral Therapy in HIV / AIDS patients : A
Belgrade cohort study.
Vojn Pregl
. 2014;71(8):746-50.
43.
Caron-debarle M, Lagathu C, Boccara F, Vigouroux C, Capeau J.
HIV-associated Lipodystrophy : from fat injury to premature aging.
Trends Mol
Med
. 2010;16(5):218-29.
44.
Domingo P, Estrada V, Lopez-Aldeguer J, Villaroya F, Martinez E. Fat
Redistribution Syndromes Associated with HIV-1 Infection and
Combination Antiretroviral Therapy.
AIDS Rev
. 2012;14:112-23.
2015;9(7):5-8.
46.
Alomar MJ. Factors Affecting the Development of Adverse Drug Reactions
(Review article).
Saudi Pharm J
. 2014;22(2):83-94.
47.
Bezu H, Seifu D, Yimer G, Mebrhatu T. Prevalence and Risk Factors of
Adverse Drug Reactions Associated Multidrug Resistant Tuberculosis
Treatments in Selected Treatment Centers in Addis Ababa Ethiopia.
J
Tuberc Res
. 2014;(September):144-54.
48.
Ambreen K, Sharma R, Singh KP, Kumar S. Anti-Tuberculosis
Drug-Induced Hepatotoxicity : A Review.
PLoS ONE
. 2014;5:423-37.
49.
Bonnet M, Baudin E, Jani I V, Nunes E, Verhoustraten F, Calmy A,
et al.
Incidence of Paradoxical Tuberculosis-Associated Immune Reconstitution
Inflammatory Syndrome and Impact on Patient Outcome.
PLoS ONE
.
2013;8(12):1-10.
50.
Assob JCN, Nde PF, Nsagha DS, Njunda AL, Ngum NM, Ngowe MN.
AIDS & Clinical Incidence and Risk Factors of Anti-tuberculosis Drugs
Induced Hepatotoxicity in HIV / AIDS Patients Attending the Limbe and
Buea Regional Hospitals.
J AIDS Clin Res
. 2014;5(3).
51.
Chiang Y, Lin Y, Lee J, Lee C, Chen H. Tobacco Consumption is a
Reversible Risk Factor Associated with Reduced Successful Treatment
Outcomes of Anti-tuberculosis Therapy.
Int J Infect Dis
.
2012;16(2):e130-e135.
53.
Eluwa GI, Badru T, Akpoigbe KJ. Adverse Drug Reactions to
Antiretroviral Therapy ( ARVs ): incidence, type and risk factors in
Nigeria.
BMC Clin Pharmacol
. 2012;12(1):7.
54.
Sterling TR, Pham PA, Chaisson RE. HIV Infection
–
Related
Tuberculosis : Clinical Manifestations and Treatment.
Clin Infect Dis
.
2010;37232:223-30.
55.
Raviglione M, Yew WW, Migliori GB. Clinical Management of
Tuberculosis and HIV-1 Co-infection.
Eur Respir J
. 2010;36(6):1460-81.
56.
Weinberg JL, Kovarik CL. The WHO Clinical Staging System for
HIV/AIDS.
Am Med Assoc J Ethics
. 2010;12(3):202-6.
57.
Lima M de FS de, Melo HRL de. Hepatotoxicity Induced by
Antituberculosis Drugs among Patients Coinfected with HIV and
Tuberculosis.
Cad Saúde Pública, Rio Janeiro
. 2012;28(4):698-708.
58.
Breen RAM, Miller RF, Gorsuch T, Smith CJ, Schwenk A, Holmes W, et
al. Adverse Events and Treatment Interuption in Tuberculosis Patients With
and Without HIV Co-infection.
Thorax
. 2006;61:791-4.
59.
Kadima JN, Mukanyangezi MF, Uwizeye CB. Effectiveness and Safety of
Concurrent Use of First-Line Antiretroviral and Antituberculous Drugs in
Rwanda.
J Trop Med
. 2014;2014:9 pages.
Lampiran 4. Output hasil statistik
Frequency Table
jenis_kelamin
Frequency Percent Valid Percent Cumulative Percent
Frequency Percent Valid Percent Cumulative Percent
Frequency Percent Valid Percent Cumulative Percent
Frequency Percent Valid Percent Cumulative Percent
Tidak 46 51.1 57.5 100.0
Total 80 88.9 100.0
Missing System 10 11.1
Total 90 100.0
IMT_preobese
Frequency Percent Valid Percent Cumulative Percent
Valid
Ya 5 5.6 6.3 6.3
Tidak 75 83.3 93.8 100.0
Total 80 88.9 100.0
Missing System 10 11.1
Total 90 100.0
imunodefisiensi
Frequency Percent Valid Percent Cumulative Percent
Valid
berat 85 94.4 94.4 94.4
tidak 5 5.6 5.6 100.0
Total 90 100.0 100.0
TBparu_BTApos
Frequency Percent Valid Percent Cumulative Percent
Valid
Ya 13 14.4 14.4 14.4
Tidak 77 85.6 85.6 100.0
TBparu_BTAneg
Frequency Percent Valid Percent Cumulative Percent
Frequency Percent Valid Percent Cumulative Percent
Frequency Percent Valid Percent Cumulative Percent
Frequency Percent Valid Percent Cumulative Percent
Valid
3 62 68.9 68.9 68.9
4 28 31.1 31.1 100.0
koinfeksi
Frequency Percent Valid Percent Cumulative Percent
Valid
Ada 5 5.6 5.6 5.6
tidak ada 85 94.4 94.4 100.0
Total 90 100.0 100.0
OAT
Frequency Percent Valid Percent Cumulative Percent
Valid
dosis optimal 88 97.8 97.8 97.8
dosis tidak optimal 2 2.2 2.2 100.0
Total 90 100.0 100.0
ART
Frequency Percent Valid Percent Cumulative Percent
Valid lini 1 90 100.0 100.0 100.0
efek_samping
Frequency Percent Valid Percent Cumulative Percent
Valid
ada 21 23.3 23.3 23.3
tidak ada 69 76.7 76.7 100.0
lama
Frequency Percent Valid Percent Cumulative Percent
jenis_kelamin * efek_samping
Crosstab
efek_samping Total
Chi-Square Tests
Continuity Correctionb .003 1 .955
Likelihood Ratio .116 1 .733
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 5.60.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for jenis_kelamin (Pria / Wanita) 1.216 .391 3.782
For cohort efek_samping = ada 1.164 .478 2.830
For cohort efek_samping = tidak ada .957 .748 1.224
N of Valid Cases 90
usia * efek_samping
Crosstab
efek_samping Total
ada tidak ada
usia <60
Count 21 67 88
% within usia 23.9% 76.1% 100.0%
Continuity Correctionb .000 1 1.000
Likelihood Ratio 1.077 1 .299
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .47.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
N of Valid Cases 90
IMT_underweight * efek_samping
Crosstab
efek_samping Total
ada tidak ada
Continuity Correctionb .000 1 1.000
Likelihood Ratio .019 1 .890
Linear-by-Linear Association
.019 1 .891
N of Valid Cases 80
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 9.26.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for IMT_underweight (Ya / Tidak) 1.075 .383 3.015
For cohort efek_samping = ada 1.057 .481 2.321
For cohort efek_samping = tidak ada .983 .770 1.255
N of Valid Cases 80
IMT_normal * efek_samping
Crosstab
efek_samping Total
Chi-Square Tests
Continuity Correctionb .051 1 .821
Likelihood Ratio .240 1 .624
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 8.08.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for IMT_normal (Ya / Tidak) 1.296 .460 3.649
For cohort efek_samping = ada 1.218 .556 2.667
For cohort efek_samping = tidak ada .940 .730 1.210
N of Valid Cases 80
IMT_preobese * efek_samping
Crosstab
efek_samping Total
ada tidak ada
IMT_preobese Ya
Count 0 5 5
Expected Count 1.2 3.8 5.0
% of Total 0.0% 6.3% 6.3%
Continuity Correctionb .557 1 .456
Likelihood Ratio 2.814 1 .093
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.19.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort efek_samping = tidak ada 1.339 1.174 1.528
imunodefisiensi * efek_samping
Crosstab
efek_samping Total
ada tidak ada
imunodefisiensi
berat
Count 20 65 85
Expected Count 19.8 65.2 85.0
% within imunodefisiensi 23.5% 76.5% 100.0%
% of Total 22.2% 72.2% 94.4%
tidak
Count 1 4 5
Expected Count 1.2 3.8 5.0
% within imunodefisiensi 20.0% 80.0% 100.0%
% of Total 1.1% 4.4% 5.6%
Total
Count 21 69 90
Expected Count 21.0 69.0 90.0
% within imunodefisiensi 23.3% 76.7% 100.0%
% of Total 23.3% 76.7% 100.0%
Continuity Correctionb .000 1 1.000
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.17.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for imunodefisiensi (berat / tidak) 1.231 .130 11.653
For cohort efek_samping = ada 1.176 .196 7.078
For cohort efek_samping = tidak ada .956 .607 1.505
N of Valid Cases 90
TBparu_BTApos * efek_samping
Crosstab
efek_samping Total
Chi-Square Tests
Continuity Correctionb .143 1 .705
Likelihood Ratio .581 1 .446
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 3.03.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for TBparu_BTApos (Ya / Tidak) .555 .113 2.730
For cohort efek_samping = ada .623 .164 2.365
For cohort efek_samping = tidak ada 1.123 .862 1.464
N of Valid Cases 90
TBparu_BTAneg * efek_samping
Crosstab
efek_samping Total
ada tidak ada
TBparu_BTAneg Ya
Count 18 45 63
Expected Count 14.7 48.3 63.0
% within TBparu_BTAneg 28.6% 71.4% 100.0%
Tidak
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.30.
b. Computed only for a 2x2 table
Chi-Square Tests
Continuity Correctionb 2.319 1 .128
Likelihood Ratio 3.570 1 .059
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.30.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for TBparu_BTAneg (Ya / Tidak) 3.200 .856 11.965
For cohort efek_samping = ada 2.571 .826 8.009
N of Valid Cases 90
TBextraparu * efek_samping
Crosstab
efek_samping Total
ada tidak ada
Continuity Correctionb .526 1 .468
Likelihood Ratio 2.745 1 .098
Linear-by-Linear Association
1.593 1 .207
N of Valid Cases 90
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.17.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort efek_samping = tidak ada 1.328 1.176 1.500
N of Valid Cases 90
TBparu_extraparu * efek_samping
Crosstab
efek_samping Total
ada tidak ada
TBparu_extraparu Ya
Count 1 8 9
Expected Count 2.1 6.9 9.0
% within TBparu_extraparu 11.1% 88.9% 100.0%
% of Total 1.1% 8.9% 10.0%
Tidak
Count 20 61 81
Expected Count 18.9 62.1 81.0
% within TBparu_extraparu 24.7% 75.3% 100.0%
% of Total 22.2% 67.8% 90.0%
Total
Count 21 69 90
Expected Count 21.0 69.0 90.0
% within TBparu_extraparu 23.3% 76.7% 100.0%
Chi-Square Tests
Continuity Correctionb .248 1 .618
Likelihood Ratio .965 1 .326
a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 2.10.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for TBparu_extraparu (Ya / Tidak) .381 .045 3.238
For cohort efek_samping = ada .450 .068 2.969
For cohort efek_samping = tidak ada 1.180 .908 1.535
N of Valid Cases 90
stadium_HIV * efek_samping
Crosstab
efek_samping Total
ada tidak ada
stadium_HIV 3
Count 17 45 62
Expected Count 14.5 47.5 62.0
% within stadium_HIV 27.4% 72.6% 100.0%
4
Continuity Correctionb 1.198 1 .274
Likelihood Ratio 1.987 1 .159
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.53.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for stadium_HIV (3 / 4) 2.267 .685 7.500
For cohort efek_samping = ada 1.919 .711 5.184
For cohort efek_samping = tidak ada .847 .683 1.050
koinfeksi * efek_samping
Crosstab
efek_samping Total
ada tidak ada
Continuity Correctionb .526 1 .468
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.17.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort efek_samping = tidak ada 1.328 1.176 1.500
N of Valid Cases 90
OAT * efek_samping
Crosstab
efek_samping Total
ada tidak ada
OAT
dosis optimal
Count 21 67 88
Expected Count 20.5 67.5 88.0
% within OAT 23.9% 76.1% 100.0%
% of Total 23.3% 74.4% 97.8%
dosis tidak optimal
Count 0 2 2
Expected Count .5 1.5 2.0
% within OAT 0.0% 100.0% 100.0%
% of Total 0.0% 2.2% 2.2%
Total
Count 21 69 90
Expected Count 21.0 69.0 90.0
% within OAT 23.3% 76.7% 100.0%
Chi-Square Tests
Continuity Correctionb .000 1 1.000
Likelihood Ratio 1.077 1 .299
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is .47.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort efek_samping = tidak ada .761 .677 .856
N of Valid Cases 90
ART * efek_samping
Crosstab
efek_samping Total
Expected Count 21.0 69.0 90.0
% within ART 23.3% 76.7% 100.0%
% of Total 23.3% 76.7% 100.0%
Chi-Square Tests
Value
Pearson Chi-Square .a
N of Valid Cases 90
a. No statistics are computed because ART is a constant.
Risk Estimate
Value
Odds Ratio for ART (lini 1 / .) .a
a. No statistics are computed because ART is a constant.
lama * efek_samping
Crosstab
efek_samping Total
Expected Count 21.0 69.0 90.0
Continuity Correctionb 53.639 1 .000
Likelihood Ratio 63.627 1 .000
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 6.77.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort efek_samping = tidak ada .276 .153 .497
N of Valid Cases 90
fase_intensif * efek_samping
Crosstab
efek_samping Total
Ya Tidak
fase_intensif Ya
Count 17 8 25
% within fase_intensif 68.0% 32.0% 100.0%
Continuity Correctionb .529 1 .467
Likelihood Ratio 2.819 1 .093
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.10.
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort efek_samping = Ya .680 .520 .890
N of Valid Cases 29
fase_lanjutan * efek_samping
Crosstab
efek_samping Total
Ya Tidak
Likelihood Ratio 2.819 1 .093
Fisher's Exact Test .552 .252
Linear-by-Linear Association
1.707 1 .191
N of Valid Cases 29
a. 2 cells (50.0%) have expected count less than 5. The minimum expected count is 1.10.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort efek_samping = Ya 1.471 1.124 1.924
